Biogen Inc Drug Patent Portfolio
Biogen Inc owns 3 orange book drugs protected by 23 US patents Given below is the list of Biogen Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11884696 | Crystalline 19-nor C3,3-disubstituted C21-n-pyrazolyl steroid | 24 Dec, 2037 | Active |
| US11236121 | Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid | 23 Aug, 2037 | Active |
| US10959972 | Methods of treating multiple sclerosis | 16 Nov, 2035 | Active |
| US11007166 | Methods of treating multiple sclerosis | 16 Nov, 2035 | Active |
| US11007167 | Methods of treating multiple sclerosis | 16 Nov, 2035 | Active |
| US11129806 | Methods of treating multiple sclerosis | 16 Nov, 2035 | Active |
| US11246850 | Methods of treating multiple sclerosis | 16 Nov, 2035 | Active |
| US10391160 | Dimethyl fumarate and vaccination regimens | 13 Mar, 2035 | Active |
| US10555993 | Dimethyl fumarate and vaccination regimens | 13 Mar, 2035 | Active |
| US10994003 | Dimethyl fumarate and vaccination regimens | 13 Mar, 2035 | Active |
| US10172871 | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof | 17 Apr, 2034 | Active |
| US10342810 | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof | 17 Apr, 2034 | Active |
| US9512165 | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof | 17 Apr, 2034 | Active |
| US10080733 | Prodrugs of fumarates and their use in treating various diseases | 20 Sep, 2033 | Active |
| US8669281 | Prodrugs of fumarates and their use in treating various diseases | 20 Sep, 2033 | Active |
| US9090558 | Prodrugs of fumarates and their use in treating various diseases | 20 Sep, 2033 | Active |
| US8399514 | Treatment for multiple sclerosis | 07 Feb, 2028 | Active |
| US7320999 | Dimethyl fumarate for the treatment of multiple sclerosis | 18 May, 2020 | Expired |
| US6509376 | Utilization of dialkyfumarates | 29 Oct, 2019 | Expired |
| US8759393 | Utilization of dialkylfumarates | 04 Jul, 2018 | Expired |
| US7619001 | Utilization of dialkylfumarates | 01 Apr, 2018 | Expired |
| US7803840 | Utilization of dialkylfumarates | 01 Apr, 2018 | Expired |
| US8524773 | Utilization of dialkylfumarates | 01 Apr, 2018 | Expired |
Latest Legal Activities on Biogen Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Biogen Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Resp. to req. for info. sent under 37 CFR 1.750 | 03 Jun, 2024 | US8669281 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 May, 2024 | US9512165 |
|
Withdrawal of Application for PTE
Critical
| 01 May, 2024 | US9090558 |
|
Withdrawal of Application for PTE
Critical
| 01 May, 2024 | US10080733 |
| Requirement for information sent under 37 CFR 1.750 | 04 Apr, 2024 | US9090558 |
| Requirement for information sent under 37 CFR 1.750 | 04 Apr, 2024 | US10080733 |
| Requirement for information sent under 37 CFR 1.750 | 04 Apr, 2024 | US8669281 |
| Notice of Final Determination -Election Required | 29 Mar, 2024 | US8669281 |
| Notice of Final Determination -Election Required | 29 Mar, 2024 | US9090558 |
| Notice of Final Determination -Election Required | 29 Mar, 2024 | US10080733 |
|
Expire Patent
Critical
| 18 Mar, 2024 | US10555993 |
| Initial letter Re: PTE Application to regulating agency | 05 Mar, 2024 | US10172871 |
| Initial letter Re: PTE Application to regulating agency | 05 Mar, 2024 | US10342810 |
| Initial letter Re: PTE Application to regulating agency | 05 Mar, 2024 | US11236121 |
| Initial letter Re: PTE Application to regulating agency | 05 Mar, 2024 | US9512165 |
Biogen Inc's Drug Patent Litigations
Biogen Inc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 01, 2015, against patent number US8399514. The petitioner Coalition for Affordable Drugs V LLC, challenged the validity of this patent, with Biogen MA Inc. as the respondent. Click below to track the latest information on how companies are challenging Biogen Inc's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8399514 | July, 2018 |
Final Written Decision
(03 Feb, 2023)
| Biogen MA Inc. | Mylan Pharmaceuticals Inc. et al. |
| US8399514 | March, 2019 |
Terminated
(11 Sep, 2019)
| Biogen MA Inc. | Sawai USA, Inc. et al. |
| US8399514 | September, 2015 |
FWD Entered
(21 Mar, 2017)
| Biogen Idec MA Inc | Coalition For Affordable Drugs V LLC |
| US8759393 | April, 2015 |
Terminated-Denied
(27 Oct, 2015)
| Biogen International GmbH | Coalition For Affordable Drugs V LLC |
| US8399514 | May, 2015 |
Terminated-Denied
(02 Sep, 2015)
| Biogen MA Inc. | Coalition for Affordable Drugs V LLC |
Biogen Inc Drug Patents' Oppositions Filed in EPO
Biogen Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 05, 2014, by Zentiva K.S.. This opposition was filed on patent number EP08725256A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP13169139A | Apr, 2023 | BIOGARAN | Granted and Under Opposition |
| EP13169139A | Apr, 2023 | Dr. Schön, Neymeyr & Partner Patentanwälte mbB | Granted and Under Opposition |
| EP13169139A | Apr, 2023 | Kraus & Weisert Patentanwälte PartGmbB | Granted and Under Opposition |
| EP13169139A | Apr, 2023 | Glenmark Pharmaceuticals Europe Ltd | Granted and Under Opposition |
| EP13169139A | Apr, 2023 | Accord Healthcare Ltd | Granted and Under Opposition |
| EP13169139A | Apr, 2023 | Adalvo Ltd. | Granted and Under Opposition |
| EP13169139A | Mar, 2023 | TEVA PHARMACEUTICAL INDUSTRIES, LTD. | Granted and Under Opposition |
| EP13169139A | Feb, 2023 | Stada-Arzneimittel Aktiengesellschaft | Granted and Under Opposition |
| EP13169139A | Oct, 2022 | G. L. Pharma GmbH | Granted and Under Opposition |
| EP13169139A | Sep, 2022 | Zentiva k.s. | Granted and Under Opposition |
| EP13169139A | Jul, 2022 | Polpharma S.A. | Granted and Under Opposition |
| EP13169139A | Jul, 2022 | Hexal AG | Granted and Under Opposition |
| EP13169139A | Jul, 2022 | neuraxpharm Arzneimittel GmbH | Granted and Under Opposition |
| EP13169139A | Jul, 2022 | Generics [UK] Limited (trading as Mylan) | Granted and Under Opposition |
| EP14767892A | Mar, 2019 | Generics (UK) Ltd | Granted and Under Opposition |
| EP14767892A | Mar, 2019 | Hexal AG | Granted and Under Opposition |
| EP14767892A | Mar, 2019 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP08725256A | Feb, 2014 | Actavis Group PTC ehf | Revoked |
| EP08725256A | Feb, 2014 | Synthon B.V. | Revoked |
| EP08725256A | Feb, 2014 | Forward Pharma A/S | Revoked |
| EP08725256A | Feb, 2014 | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. | Revoked |
| EP08725256A | Feb, 2014 | Generics [UK] Limited | Revoked |
| EP08725256A | Feb, 2014 | Gallafent, Antony Xavier | Revoked |
| EP08725256A | Feb, 2014 | European Opposition Limited | Revoked |
| EP08725256A | Feb, 2014 | G. L. Pharma GmbH | Revoked |
| EP08725256A | Feb, 2014 | Hexal AG | Revoked |
| EP08725256A | Feb, 2014 | Zentiva k.s. | Revoked |
Biogen Inc's Family Patents
Biogen Inc Drug List
Given below is the complete list of Biogen Inc's drugs and the patents protecting them.
1. Tecfidera
Tecfidera is protected by 15 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10959972 | Methods of treating multiple sclerosis |
16 Nov, 2035
(11 years from now)
| Active |
| US11007166 | Methods of treating multiple sclerosis |
16 Nov, 2035
(11 years from now)
| Active |
| US11007167 | Methods of treating multiple sclerosis |
16 Nov, 2035
(11 years from now)
| Active |
| US11129806 | Methods of treating multiple sclerosis |
16 Nov, 2035
(11 years from now)
| Active |
| US11246850 | Methods of treating multiple sclerosis |
16 Nov, 2035
(11 years from now)
| Active |
| US10391160 | Dimethyl fumarate and vaccination regimens |
13 Mar, 2035
(10 years from now)
| Active |
| US10555993 | Dimethyl fumarate and vaccination regimens |
13 Mar, 2035
(10 years from now)
| Active |
| US10994003 | Dimethyl fumarate and vaccination regimens |
13 Mar, 2035
(10 years from now)
| Active |
| US8399514 | Treatment for multiple sclerosis |
07 Feb, 2028
(3 years from now)
| Active |
| US7320999 | Dimethyl fumarate for the treatment of multiple sclerosis |
18 May, 2020
(4 years ago)
| Expired |
| US6509376 | Utilization of dialkyfumarates |
29 Oct, 2019
(5 years ago)
| Expired |
| US8759393 | Utilization of dialkylfumarates |
04 Jul, 2018
(6 years ago)
| Expired |
| US7619001 | Utilization of dialkylfumarates |
01 Apr, 2018
(6 years ago)
| Expired |
| US7803840 | Utilization of dialkylfumarates |
01 Apr, 2018
(6 years ago)
| Expired |
| US8524773 | Utilization of dialkylfumarates |
01 Apr, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tecfidera's drug page
2. Vumerity
Vumerity is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10080733 | Prodrugs of fumarates and their use in treating various diseases |
20 Sep, 2033
(8 years from now)
| Active |
| US8669281 | Prodrugs of fumarates and their use in treating various diseases |
20 Sep, 2033
(8 years from now)
| Active |
| US9090558 | Prodrugs of fumarates and their use in treating various diseases |
20 Sep, 2033
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vumerity's drug page
3. Zurzuvae
Zurzuvae is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11884696 | Crystalline 19-nor C3,3-disubstituted C21-n-pyrazolyl steroid |
24 Dec, 2037
(13 years from now)
| Active |
| US11236121 | Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid |
23 Aug, 2037
(12 years from now)
| Active |
| US10172871 | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
17 Apr, 2034
(9 years from now)
| Active |
| US10342810 | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
17 Apr, 2034
(9 years from now)
| Active |
| US9512165 | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
17 Apr, 2034
(9 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zurzuvae's drug page